- 파이프라인
-
한미약품은 축적된 연구 개발 기술력을 바탕으로 항암, 대사성, 심혈관 · 신장계, 희귀질환 치료제 분야에서
다양한 혁신신약을 개발하고 있습니다.
주요 파이프라인 소개
한미약품과 인류의 건강을 위한 창조와 혁신 그리고 도전 정신을 함께 할 파트너사를 찾습니다.
HM15136 (LAPSGlucagon analog)
OVERVIEW
HM15136 is a long-acting glucagon analog chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker (LAPSCOVERY). The main physiological effects of glucagon receptor agonism (increasing glycogenolysis and gluconeogenesis) and favorable physicochemical and PK properties suggest therapeutic potential of HM15136 in subjects with chronic hypoglycemic diseases such as congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBH). HM15136 received orphan drug designation from the FDA, EMA, and MFDS for the treatment of CHI, and received rare pediatric disease in the U.S FDA. HM15136 is also designated as an orphan drug from the EMA for the treatment of insulin autoimmune syndrome.
Additionally, glucagon receptor agonism is also associated with increased energy expenditure and improvement of various cardiometabolic risk factors. In nonclinical studies, improved lipid profile, kidney function, and blood pressure were observed along with a remarkable weight loss effect.
Additionally, glucagon receptor agonism is also associated with increased energy expenditure and improvement of various cardiometabolic risk factors. In nonclinical studies, improved lipid profile, kidney function, and blood pressure were observed along with a remarkable weight loss effect.
Glucagon agonism
(for chronic
hypoglycemic disease)
Glucagon agonism
(for obesity)
Ultra-long duration of action
For Chronic Hypoglycemic Disease
For Obesity
CLINICAL DEVELOPMENT
A phase 1a and 1b study were completed (NCT04032782, NCT04167553).
A phase 2a study is currently ongoing with CHI patients in US, UK, Germany and Israel. (NCT04732416).
A phase 2a study is currently ongoing with CHI patients in US, UK, Germany and Israel. (NCT04732416).
PUBLICATIONS
- A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting
- Journal, Diabetes Obes Metab. 2022; 24(3): 411-420
- A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism
- Journal, Scientific Reports. 2022; 12:16765
- Beneficial effects on metabolic disorders by a long-acting glucagon analogue, HM15136, in pre-clinical models
- Oral presentation, European association for the study of diabetes (EASD) 58th Annual meeting, 2022
- Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders (657-P)
- Poster, American diabetes association (ADA) 81st Scientific sessions, 2021
- Sustained Glucagon Effect on Cardiovascular Renal and Metabolic Disorders Mediated by a Long-Acting Glucagon Analog, HM15136, in Animal Disease Models (658-P)
- Poster, American diabetes association (ADA) 81st Scientific sessions, 2021
- Potent weight loss effects and mechanism of a novel long-acting Glucagon analog, HM15136, in animal models
- Poster, American diabetes association (ADA) 80th Scientific sessions, 2020
- Beneficial effects of a novel long-acting glucagon analog, HM15136, on obesity and obesity related metabolic disorders in animal models
- Poster, American diabetes association (ADA) 80th Scientific sessions, 2020
- A double-blind, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects
- Poster, American diabetes association (ADA) 80th Scientific sessions, 2020
- Sustained Glucagon effect on blood glucose and improvements of insulin resistance mediated by a novel long-acting Glucagon analogue, HM15136, in animal models
- Poster, European association for the study of diabetes (EASD) 55th Annual meeting, 2019
- Potential of a novel long-acting Glucagon analogue, HM15136, for the treatment of obesity
- Poster, European association for the study of diabetes (EASD) 55th Annual meeting, 2019
- Potential of a novel long-acting Glucagon analog, HM15136, for the treatment of obesity
- Poster, American diabetes association (ADA) 79th Scientific sessions, 2019
- Potent weight loss mechanism by a novel long-acting Glucagon analog, HM15136, in animal models
- Poster, American diabetes association (ADA) 79th Scientific sessions, 2019
- Sustained Glucagon effect on blood glucose and improvements of insulin resistance mediated by a novel long-acting Glucagon analog, HM15136, in animal models
- Poster, American diabetes association (ADA) 79th Scientific sessions, 2019
- Therapeutic potential of novel combination of a long-acting Glucagon analog (HM15136) and antidiabetic drugs for the treatment of obesity
- Poster, American diabetes association (ADA) 79th Scientific sessions, 2019
- A novel long-acting Glucagon analog (HM15136) offers favorable stability, PK/PD, and therapeutic potentials in CHI (congenital hyperinsulinism) animal model
- Poster, European association for the study of diabetes (EASD) 53rd Annual meeting, 2017
- A novel long-acting Glucagon analog (HM15136) offers favorable stability, PK, and therapeutic potentials in congenital hyperinsulinism animal model
- Poster, American diabetes association (ADA) 77th Scientific sessions, 2017